Pharma Boom Is Not a Free Pass to Higher Rates, Pharma.Aero Warns

Forwarders hoping that booming demand for high-value pharmaceutical therapies translates into fatter margins received a blunt correction this week: Pharma.Aero secretary general Frank van Gelder says the days of treating valuable cargo as a licence to charge more are over.

The industry body's message, delivered to The Loadstar, cuts against a comfortable assumption in freight forwarding — that as pharma products rise in value, so should the rates logistics operators can command. Van Gelder argues the opposite is now true: shippers want evidence, not labels.

What changed in pharma logistics pricing?

The core shift is a decoupling of demand from tonnage. "Demand for complex, high-value and time-sensitive therapies can increase, even when traditional tonnage grows more slowly or shifts between modes," van Gelder explained. In other words, a forwarder may see invoice values climb while actual volumes stagnate or migrate between air, ocean and road.

That asymmetry matters commercially. If volumes do not grow, revenue growth must come from premium services — and those premiums are no longer automatic. "Premium prices cannot be justified merely by applying a pharma label," van Gelder said. "Profitability will depend on specialisation, measurable quality, and intelligent cost management."

He was equally direct on what shippers now demand before paying up. "Operators must demonstrate what their services actually protect," he said, listing "product integrity, continuity of treatment, predictability, and lower total risk" as the criteria. A pharma sticker on a rate sheet, by implication, protects nothing and justifies nothing.

Where does the money actually come from?

Van Gelder's prescription is unglamorous: specialist capabilities, demonstrable quality metrics, and disciplined cost management. None of these come cheap. Pharma logistics requires sustained investment in qualified infrastructure, handling equipment and trained personnel — costs that are substantial precisely because different products carry very different handling requirements.

For forwarders, that variance is the commercial trap. The cost of maintaining appropriate handling standards across a diverse pharma portfolio can be significant, while the pricing power to recover those costs depends entirely on proving the service protects the product. An operator that cannot show measurable quality will carry the cost base without the premium.

Van Gelder frames the sector's wider tension as what he calls the "healthcare pressure point": pharmaceutical innovation pressing from one side, affordability, access and rising costs from the other. The challenge, he said, is "not simply whether we can transport the next generation of medicines", but "whether we can help make them accessible and affordable to patients".

That framing pushes the affordability question down the supply chain. If payers and health systems squeeze pharma companies on price, logistics providers will feel the pressure in their own rate negotiations — another reason, in van Gelder's telling, why cost management sits alongside specialisation as a survival skill rather than an optional discipline.

What should forwarders do next?

The structural backdrop reinforces the point rather than softening it. Van Gelder describes a "multi-polar pharma world" in which China, India and the Middle East are all reshaping the geographical spread of production and distribution, with "multi-node supply chains" as the future of the sector. More nodes mean more handoffs, more modes and more places where product integrity must be proven — compounding both the cost burden and the case for genuine specialisation.

The trajectory, on his evidence, points one way: therapeutic value will keep rising faster than tonnage, and shippers will keep tightening their definition of what earns a premium. Forwarders that invest in qualified capability and can quantify it stand to gain the business; those relying on the pharma label alone should expect that argument to fail, increasingly quickly.